VRM
ARKG icon

Vectors Research Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Vectors Research Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$6K – 472
2021
Q4 		$6K Buy
+100
New +$6.91K ﹤0.01% 481

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Vectors Research Management's ARKG Position: Q1 2022 in Review

Vectors Research Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 100 shares — an estimated $6K sold.

Vectors Research Management first reported a position in ARKG in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • Vectors Research Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • Vectors Research Management sold 100 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $6K.
  • Vectors Research Management first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 1 quarter.
  • Vectors Research Management's ARK Genomic Revolution ETF position peaked at $6K in Q4 2021.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Vectors Research Management's 13F filing for Q1 2022, filed 16 May 2022.